Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study

A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(−1), capecitabine 1300 mg m(−2) daily for 2 weeks and gemcitabine 1000 mg m(−2) weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free su...

Descripción completa

Detalles Bibliográficos
Autores principales: Javle, M, Yu, J, Garrett, C, Pande, A, Kuvshinoff, B, Litwin, A, Phelan, J, Gibbs, J, Iyer, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714236/
https://www.ncbi.nlm.nih.gov/pubmed/19491904
http://dx.doi.org/10.1038/sj.bjc.6605099
Descripción
Sumario:A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(−1), capecitabine 1300 mg m(−2) daily for 2 weeks and gemcitabine 1000 mg m(−2) weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).

Ejemplares similares